Semaglutide is the compound behind Ozempic and Wegovy — two names that became part of the broader conversation about weight and metabolic health in a way few medications ever have. It works by mimicking GLP-1, a gut hormone that tells your brain you have eaten, slows stomach emptying, and helps your body manage blood sugar. Originally developed for type 2 diabetes, it became one of the most studied medications for obesity after clinical trials showed weight loss results that exceeded anything previously approved in that category. It is available as a weekly injection or a daily pill.
Weight Management
The STEP trial series tested weekly injectable semaglutide (brand: Wegovy) in people with obesity. Average weight loss was around 15% of body weight over 68 weeks at the 2.4mg dose — more than had been seen with any previous approved weight medication.
Type 2 Diabetes
The SUSTAIN trial series tested semaglutide for blood sugar control. It is approved for type 2 diabetes in both injectable (Ozempic) and oral (Rybelsus) forms and reduces HbA1c significantly compared to placebo and many existing treatments.
Cardiovascular Outcomes
The SELECT trial enrolled over 17,000 people with overweight or obesity and established cardiovascular disease. Semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo over about 3 years — a landmark result.
Kidney Disease
The FLOW trial found semaglutide significantly reduced the progression of chronic kidney disease in people with type 2 diabetes and CKD, adding kidney protection to its established cardiovascular benefits.
Average weight loss of approximately 15% of body weight in the STEP trials at 68 weeks.
20% reduction in major cardiovascular events in the SELECT trial over roughly 3 years.
Significant HbA1c reductions across multiple large diabetes trials.
Slowed progression of chronic kidney disease in the FLOW trial.
Weight regain observed after stopping the medication, consistent with its mechanism.
Long-term data beyond 3-5 years are still limited for most outcomes. The cardiovascular benefit was demonstrated in people who already had established cardiovascular disease — whether it extends equally to lower-risk populations is still being studied. The pill form of semaglutide is absorbed less consistently than the injectable — how much actually reaches the bloodstream depends on whether it is taken correctly on an empty stomach, which affects how reliably it works. GI side effects are common at initiation.
GLP-1 is released from the gut after eating and sends signals that tell the brain you have eaten enough, slow stomach emptying so food is processed gradually, and stimulate insulin release only when blood sugar is actually elevated. Semaglutide is an engineered version of GLP-1 with modifications that make it last much longer — about a week for the injectable form. By activating GLP-1 receptors continuously at a low level, it reduces baseline hunger, slows stomach emptying between meals, and improves the body's blood sugar regulation over time.
FDA-approved with a large safety dataset from years of trials and real-world use. The most common side effects are gastrointestinal — nausea, vomiting, constipation, diarrhea — and tend to be strongest when starting or stepping up the dose before settling down. It carries the FDA's most prominent safety label about thyroid C-cell tumors seen in rodent studies; the relevance to humans is not established, but it is avoided in people with certain thyroid cancer histories. Rare cases of pancreatitis and vision changes have been reported. Not recommended during pregnancy.
High Evidence
This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.
Published Research Ranges
0.25–2.4mg weekly (STEP trials)
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine • 2021
• DOI: 10.1056/NEJMoa2032183
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease
Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.